Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ID: DRG0UBXSP)
ADC Name
DB-1418
Synonyms
DB-1418; AVZO-1418
   Click to Show/Hide
Organization
Duality Biotherapeutics (DualityBio) (Originator);Avenzo Therapeutics
Drug Status
Phase 1/2
Drug-to-Antibody Ratio
6
Structure
Antibody Name
Anti-EGFR/HER3 bsAb
  Antibody Info 
Antigen Name
Epidermal growth factor receptor (EGFR); Receptor tyrosine-protein kinase erbB-3 (HER3)
  Antigen Info 
Payload Name
P1021
  Payload Info 
Payload Target
DNA topoisomerase 1 (TOP1)
  Target Info 
Linker Name
Mc-Gly-Gly-Phe-Gly
  Linker Info 
Conjugate Type
Random Cysteines
Combination Type
drozuntecan
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
Indication Phase 1 Phase 2 Phase 3 Approved
Unspecific solid tumor
1 Trials
Trial ID
pmcts00000380; NCT07038343
Lung cancer
1 Trials
Trial ID
pmcts00000380; NCT07038343
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth lnhibition value (TGl) 
83
%
Undisclosed Undisclosed
Tumor Growth lnhibition value (TGl) 
98
%
Undisclosed Undisclosed
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth lnhibition value (TGl)
83%
Method Description
In the EGFR-dominant CAL-27 model, DB-1418 demonstrated a significant tumor growth inhibition (TGI) of 83% at a dose of 1.9 mg/kg Q3W
In Vivo Model EGFR-dominant CAL-27 model
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth lnhibition value (TGl)
98%
Method Description
Notably, in an osimertinib-resistant NSCLC xenograft model with the C797S mutation, DB-1418 induced tumor regression with a TGI of 98% at a dose of 6 mg/kg Q3W.
In Vivo Model Osimertinib-resistant NSCLC xenograft model with the C797S mutation
References
Ref 1 DB-1418, a bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3, demonstrates superior and broad antitumor efficacy and favorable safety in preclinical models